Literature DB >> 28922853

A Rationale for Targeting Extracellular Regulated Kinases ERK1 and ERK2 in Glioblastoma.

Ricarda Hannen1, Maria Hauswald1, Joerg Walter Bartsch1.   

Abstract

Glioblastoma (GBM) is the most common malignant primary brain tumor. It still carries a grim prognosis and new therapies are needed. This review summarizes the current status of mechanistic insights into the function of extracellular regulated kinase (ERK) and its potential as a therapeutic target for patients with GBM. Currently, some promising ERK inhibitors are in clinical trials in tumor entities other than GBM. Here, we provide a comprehensive overview on the functions of ERK1/2 in GBM and a rationale for treatment of GBM with ERK inhibitors.
© 2017 American Association of Neuropathologists, Inc. All rights reserved.

Entities:  

Keywords:  ERK inhibitors; Extracellular regulated kinase; Glioblastoma

Mesh：

Substances：

Year:  2017        PMID： 28922853     DOI： 10.1093/jnen/nlx076

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN： 0022-3069            Impact factor:   3.685


  8 in total

Review 1.  FGF2: a novel druggable target for glioblastoma?

Authors:  Ana Jimenez-Pascual; Kelly Mitchell; Florian A Siebzehnrubl; Justin D Lathia
Journal:  Expert Opin Ther Targets       Date:  2020-03-16       Impact factor: 6.797

2.  ERK1/2 signaling regulates the immune microenvironment and macrophage recruitment in glioblastoma.

Authors:  Claire Lailler; Christophe Louandre; Mony Chenda Morisse; Thomas Lhossein; Corinne Godin; Marine Lottin; Jean-Marc Constans; Bruno Chauffert; Antoine Galmiche; Zuzana Saidak
Journal:  Biosci Rep       Date:  2019-09-13       Impact factor: 3.840

3.  Deletion of the Capn1 Gene Results in Alterations in Signaling Pathways Related to Alzheimer's Disease, Protein Quality Control and Synaptic Plasticity in Mouse Brain.

Authors:  Wenyue Su; Qian Zhou; Yubin Wang; Athar Chishti; Qingshun Q Li; Sujay Dayal; Shayan Shiehzadegan; Ariel Cheng; Clare Moore; Xiaoning Bi; Michel Baudry
Journal:  Front Genet       Date:  2020-04-09       Impact factor: 4.599

4.  Decreased DUSP26 Expression Promotes Malignant Behavior in Glioblastoma Cells via Deregulation of MAPK and Akt Signaling Pathway.

Authors:  Jiajia Chen; Yuecan Zeng; Rong Wu; Ying Xuan; Min Jiang; Hao Teng
Journal:  Front Oncol       Date:  2021-02-25       Impact factor: 6.244

5.  Elevated RGMA Expression Predicts Poor Prognosis in Patients with Glioblastoma.

Authors:  Thi Le Phan; Hyun-Jin Kim; Suk Jun Lee; Moon-Chang Choi; Sung-Hak Kim
Journal:  Onco Targets Ther       Date:  2021-09-21       Impact factor: 4.147

6.  Studies on Biological and Molecular Effects of Small-Molecule Kinase Inhibitors on Human Glioblastoma Cells and Organotypic Brain Slices.

Authors:  Julia Hörnschemeyer; Timo Kirschstein; Gesine Reichart; Christin Sasse; Jakob Venus; Anne Einsle; Katrin Porath; Michael Linnebacher; Rüdiger Köhling; Falko Lange
Journal:  Life (Basel)       Date:  2022-08-17

7.  Induction of apoptosis through extrinsic/intrinsic pathways and suppression of ERK/NF-κB signalling participate in anti-glioblastoma of imipramine.

Authors:  Fei-Ting Hsu; I-Tsang Chiang; Wei-Shu Wang
Journal:  J Cell Mol Med       Date:  2020-03-09       Impact factor: 5.310

8.  Tumor Heterogeneity and Molecular Characteristics of Glioblastoma Revealed by Single-Cell RNA-Seq Data Analysis.

Authors:  Dhanusha Yesudhas; S Akila Parvathy Dharshini; Y-H Taguchi; M Michael Gromiha
Journal:  Genes (Basel)       Date:  2022-02-25       Impact factor: 4.096
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.